Ashwagandha for Stress: What the Evidence Shows

Ashwagandha for Stress: What the Evidence Shows

By Jack Zheng, MS Pharmacy -- Founder of MIHIYO Labs

Summary

Ashwagandha can help stress, but the honest answer is modest and formulation-dependent. A 2024 meta-analysis pooling nine randomized trials and 558 participants found improvements in perceived stress, Hamilton anxiety scores, and serum cortisol versus placebo.7 The stronger trials used standardized extracts, usually around 240 to 600 mg/day for 6 to 12 weeks, rather than generic loose powder.1256 That matters for MIHIYO Labs because an oral dissolving strip (ODS) should follow dose reality, extract quality, and claim discipline rather than adaptogen hype. The evidence is strongest for short-term support in stressed adults, not for every bottle sold under the same plant name.

Does ashwagandha actually help with stress?

Yes, there is real human evidence that ashwagandha can reduce stress markers and improve some anxiety or sleep-related outcomes. The cleaner answer is not "powerful adaptogen" or "natural cortisol fix." It is that several short randomized trials show a measurable but not universal benefit, especially when the product is a standardized extract and the participants already report chronic stress, anxiety, or poor sleep.1236

That distinction matters. The clinical literature is not testing every grocery-store root powder as if it were interchangeable. It is mostly testing named extracts with defined withanolide content, controlled doses, and treatment periods of about 6 to 12 weeks.256 When readers flatten all of that into "ashwagandha works," they skip the only part that makes the evidence usable.

How might ashwagandha affect stress biology?

The main mechanistic story in the human trials is the hypothalamic-pituitary-adrenal axis, usually shortened to the HPA axis. This is the hormone signaling system that helps the body respond to stress. Cortisol is one of its major downstream signals. When the trials report lower morning cortisol alongside lower perceived-stress or anxiety scores, the authors are usually interpreting that as a less reactive stress response rather than a stimulant-like mood effect.126 Some studies report clear cortisol reductions with parallel improvements in rating scales.1256 A newer meta-analysis suggests the cortisol effect may be more consistent than the perceived-stress effect, which tells me the clinical signal is real but still heterogeneous.8

Sleep is also part of the picture. Chronic stress and poor sleep often travel together, so an ingredient that improves sleep onset, sleep efficiency, or morning alertness can look like a stress intervention even when the pathway is mixed. In a 2019 insomnia-and-anxiety trial, 300 mg of root extract twice daily for 10 weeks shortened sleep onset latency and improved sleep efficiency versus placebo.3 In a 2020 elderly cohort, 600 mg/day improved sleep quality, mental alertness, and quality-of-life scores over 12 weeks.4 Most of the better trials are swallowed extracts used consistently over weeks, not one-off rescue formats.1256

Ashwagandha may moderate a stressed HPA-axis pattern when the extract is standardized. Chronic stress drives HPA-axis signaling and cortisol output; standardized ashwagandha extracts may reduce that stress load and support sleep, but the effect depends on formulation quality. Chronic stress input Poor sleep, rumination, pressure load HPA-axis activation Higher cortisol and stress reactivity Clinical symptoms Stress scores, anxiety, sleep disruption Standardized extract Usually 240 to 600 mg daily Observed trial effects Lower cortisol, better stress and sleep scores Not every powder or bottle is equivalent Quality and endpoint heterogeneity remain Moderated stress signal Legend: clay boxes show the stress-load pathway; green boxes show where standardized ashwagandha trials report a helpful signal.

What the controlled trials and meta-analyses actually show

The broad picture is favorable, but it is not uniform.

The early 2012 placebo-controlled trial by Chandrasekhar and colleagues enrolled 64 adults with chronic stress and used 300 mg of a high-concentration root extract twice daily for 60 days. Compared with placebo, the treatment group showed significant reductions across stress-assessment scales and a substantial drop in serum cortisol, with no serious adverse events reported.1

The 2019 Lopresti study used 240 mg/day of a standardized extract for 60 days. Ashwagandha significantly improved Hamilton anxiety scores, produced a near-significant reduction on DASS-21, and reduced morning cortisol and DHEA-S versus placebo.2 The same year, Langade and colleagues studied insomnia plus anxiety rather than generic stress. Their trial used 300 mg twice daily for 10 weeks. Sleep onset latency was shorter in the treatment arm at week 10, sleep efficiency rose from 75.63 to 83.48, and anxiety scores improved versus placebo.3

The more recent trial set is still positive, but it also shows why extract names matter. In 2023, Majeed and colleagues studied a 500 mg once-daily extract standardized to 2.5% withanolides plus 5 mg piperine. The treatment group improved on Perceived Stress Scale, GAD-7, and quality-of-life scores and showed a greater reduction in morning salivary cortisol than placebo.5 In 2024, Pandit and colleagues tested a root-and-leaf aqueous extract at 125, 250, and 500 mg/day for 8 weeks and reported dose-dependent reductions in PSS, cortisol, ACTH, and salivary alpha-amylase, along with better sleep and vitality measures.6

The table below is the easiest way to keep the evidence honest.

Trial or review Extract and dose Duration Main signal Practical takeaway
Chandrasekhar 2012 Root extract, 300 mg twice daily 60 days Stress scales and serum cortisol improved vs placebo One of the core chronic-stress RCTs1
Lopresti 2019 Standardized extract, 240 mg daily 60 days HAM-A improved; morning cortisol and DHEA-S fell Supports HPA-axis moderation2
Langade 2019 Root extract, 300 mg twice daily 10 weeks Better sleep onset, sleep efficiency, and HAM-A Stronger for stress plus sleep disruption3
Kelgane 2020 Root extract, 600 mg daily 12 weeks Better QoL, sleep quality, and morning alertness Helpful, but elderly-wellbeing data is not the same as general stress data4
Majeed 2023 500 mg extract plus piperine 60 days PSS, GAD-7, QoL, and salivary cortisol improved Product-specific evidence; not every extract can borrow it5
Pandit 2024 Root-and-leaf extract, 125/250/500 mg daily 8 weeks Dose-dependent stress-biomarker and PSS improvements Low-dose effect is possible with the right extract6
Arumugam 2024 meta-analysis 9 RCTs, 558 patients Mixed PSS, Hamilton anxiety, and serum cortisol favored ashwagandha Best short summary of the positive case7
Albalawi 2025 meta-analysis 7 RCTs, pooled review Mixed Cortisol improved, perceived stress not clearly pooled Best short summary of the heterogeneity8
Most ashwagandha stress trials point in the same direction, but the certainty is uneven. Meta-analyses and individual randomized trials generally favor standardized ashwagandha extracts for cortisol, perceived stress, anxiety, and stress-linked sleep, while still warning about heterogeneity. Outcome Overall direction from trials and reviews Serum or salivary cortisol Most consistent positive signal Perceived stress scales Often improved, but less uniform Anxiety and stress-linked sleep Helpful in several targeted trials Confidence across products Weakest point: extract heterogeneity Clinical pattern: standardized extracts look better than generic product assumptions, and short-term outcome data is stronger than long-term certainty.

The two meta-analyses are worth reading together instead of choosing the more flattering one. The 2022 review by Akhgarjand and colleagues pooled 12 papers and 1,002 participants and found significant reductions in both anxiety and stress, with the most favorable stress range around 300 to 600 mg/day, but the certainty of evidence was low and heterogeneity was high.9 The 2024 review by Arumugam and colleagues was also positive on PSS, Hamilton anxiety, and cortisol.7 Then the 2025 review by Albalawi came in with a more cautious conclusion: meaningful cortisol reduction, but no clear pooled benefit on perceived stress.8

That is not a contradiction so much as a warning label. The ingredient has a real signal. The category also has inconsistent formulations, small samples, and endpoint diversity.

What this means for MIHIYO products

This is exactly the kind of topic where dosage-form discipline matters more than trend-following.

If I were trying to force ashwagandha into Mood-Boost, the first problem would not be branding. It would be payload. Most of the better stress trials are working in the rough range of 240 to 600 mg per day, often with standardized extracts and multi-week adherence.12569 That is a lot of material for a clean fast-dissolving film, especially if I care about taste, strip thickness, dissolution behavior, and the experience of actually holding the dose in the mouth.

This is where I would rather be honest than clever. Some ingredients belong in an oral film because route changes the pharmacology. Melatonin is a good example. Ashwagandha is different. The evidence base is mostly built on swallowed standardized extracts taken consistently over time, not on a mucosal-delivery advantage.

That is one reason Mood-Boost is built around the calmer-focus logic of 5-HTP and L-theanine rather than a generic "adaptogen for everything" stack. I would rather choose a format that fits the payload and the mechanism than stuff a fashionable herb into a strip just to widen the label.

The other design lesson is claim discipline. Even in the favorable trials, ashwagandha is not doing everything at once. It may lower cortisol, improve perceived stress, help sleep quality, or improve anxiety scores in selected groups. That is enough. It does not need hype language, and it definitely does not justify pretending that every unstandardized capsule on a marketplace has the same evidence behind it.

The studies cited here were run on ashwagandha extracts in research settings. They were not run on MIHIYO products.

Where this evidence still falls short

The first limitation is formulation heterogeneity. Root extract, root-and-leaf extract, high-withanolide extracts, piperine-containing formulas, and products sold under different trade names are not interchangeable.256 A positive trial on one extract is not a free pass for the whole shelf.

The second limitation is geography and sample size. Much of the stress literature comes from India and uses relatively small cohorts, often around 50 to 100 participants.1236 That does not make the findings invalid. It does mean the certainty is still lower than the confidence level suggested by supplement advertising.

The third limitation is endpoint selection. Cortisol is useful, but it is not the same thing as a person feeling better. Perceived Stress Scale scores matter, but they are subjective and can vary with context. Sleep outcomes can improve even when the broader stress story is mixed. When later meta-analyses disagree on whether the pooled stress effect is robust, that is usually a sign that these endpoints are not perfectly aligned across formulations and populations.789

The fourth limitation is long-term safety and product quality. The short trials generally report good tolerability and only mild adverse events.157 That is reassuring for short-term use, but it is not the same as having strong long-term safety data across all doses and all commercial products.

Finally, stress support is not the same claim as treating an anxiety disorder. If a person has severe anxiety, panic, depression, or persistent insomnia, an herb trial is not a substitute for proper evaluation. The best ashwagandha papers support a narrower sentence: short-term standardized supplementation may help some stressed adults, especially when sleep and anxiety symptoms overlap.379

The bottom line

The most defensible version of the ashwagandha stress evidence is this: standardized ashwagandha extracts can modestly improve stress-related outcomes in short randomized trials, and the signal is strongest when you look at cortisol, anxiety ratings, and stress-linked sleep disruption together rather than demanding one dramatic effect. The weak version of the story is "ashwagandha works." The strong version is "some well-made extracts at evidence-based doses help some stressed adults over several weeks." That is the standard I would use for product design too. If the extract quality, dose, and dosage form do not match the evidence, the label is running ahead of the science.

References

  1. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012;34(3):255-262. PMID: 23439798 / DOI: 10.4103/0253-7176.106022. <https://pubmed.ncbi.nlm.nih.gov/23439798/>
  2. Lopresti AL, Smith SJ, Malvi H, Kodgule R. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2019;98(37):e17186. PMID: 31517876 / DOI: 10.1097/MD.0000000000017186. <https://pubmed.ncbi.nlm.nih.gov/31517876/>
  3. Langade D, Kanchi S, Salve J, Debnath K, Ambegaokar D. Efficacy and safety of Ashwagandha (Withania somnifera) root extract in insomnia and anxiety: A double-blind, randomized, placebo-controlled study. Cureus. 2019;11(9):e5797. PMID: 31728244 / DOI: 10.7759/cureus.5797. <https://pubmed.ncbi.nlm.nih.gov/31728244/>
  4. Kelgane SB, Salve J, Sampara P, Debnath K. Efficacy and tolerability of Ashwagandha root extract in the elderly for improvement of general well-being and sleep: A prospective, randomized, double-blind, placebo-controlled study. Cureus. 2020;12(2):e7083. PMID: 32226684 / DOI: 10.7759/cureus.7083. <https://pubmed.ncbi.nlm.nih.gov/32226684/>
  5. Majeed M, Nagabhushanam K, Mundkur L. A standardized Ashwagandha root extract alleviates stress, anxiety, and improves quality of life in healthy adults by modulating stress hormones: Results from a randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2023;102(41):e35521. PMID: 37832082 / DOI: 10.1097/MD.0000000000035521. <https://pubmed.ncbi.nlm.nih.gov/37832082/>
  6. Pandit S, Srivastav AK, Sur TK, Chaudhuri S, Wang Y, Biswas TK. Effects of Withania somnifera extract in chronically stressed adults: A randomized controlled trial. Nutrients. 2024;16(9):1293. PMID: 38732539 / DOI: 10.3390/nu16091293. <https://pubmed.ncbi.nlm.nih.gov/38732539/>
  7. Arumugam V, Vijayakumar V, Balakrishnan A, Bhandari RB, Boopalan D, Ponnurangam R, Sankaralingam Thirupathy V, Kuppusamy M. Effects of Ashwagandha (Withania somnifera) on stress and anxiety: A systematic review and meta-analysis. Explore (NY). 2024;20(6):103062. PMID: 39348746 / DOI: 10.1016/j.explore.2024.103062. <https://pubmed.ncbi.nlm.nih.gov/39348746/>
  8. Albalawi AA. Dual impact of Ashwagandha: Significant cortisol reduction but no effects on perceived stress - A systematic review and meta-analysis. Nutr Health. 2025;31(4):1395-1408. PMID: 40746175 / DOI: 10.1177/02601060251363647. <https://pubmed.ncbi.nlm.nih.gov/40746175/>
  9. Akhgarjand C, Asoudeh F, Bagheri A, Kalantar Z, Vahabi Z, Shab-Bidar S, Rezvani H, Djafarian K. Does Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2022;36(11):4115-4124. PMID: 36017529 / DOI: 10.1002/ptr.7598. <https://pubmed.ncbi.nlm.nih.gov/36017529/>

By — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.

0 comments

Leave a comment

Please note, comments need to be approved before they are published.